Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Onconova Therapeutics, focused on developing cancer treatments, will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-16, 2022. A corporate overview by Dr. Steven Fruchtman will be available on-demand from September 12, 2022. Viewers can access the presentation here. Onconova is also conducting Phase 1 studies for its lead product, narazaciclib, and rigosertib in combination with nivolumab.

NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in the H.C. Wainwright 24^th Annual Global Investment Conference, which is taking place in a hybrid format at the Lotte New York Palace Hotel.

A corporate overview presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available on-demand beginning on Monday, September 12, 2022, at 7:00 a.m. ET. The presentation can be viewed here or on the “Corporate Events and Presentations” section of the Onconova website and will be archived for 90 days. Dr. Fruchtman and other members of the Onconova management team will also be available for virtual one-on-one meetings through the conference from September 12 – 16, 2022. Those interested in requesting a meeting should contact their H.C. Wainwright representative. 

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

What is Onconova's participation in the H.C. Wainwright conference in 2022?

Onconova Therapeutics will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-16, 2022.

When will Onconova's corporate overview be available during the conference?

The corporate overview presented by Dr. Steven Fruchtman will be available on-demand starting September 12, 2022, at 7:00 a.m. ET.

How can I view Onconova's presentation from the conference?

The presentation can be viewed online starting September 12, 2022. Access it here.

What are the ongoing clinical studies for Onconova's drug candidates?

Onconova is conducting Phase 1 dose-escalation studies for narazaciclib in the U.S. and China, and studying rigosertib in combination with nivolumab for KRAS+ non-small cell lung cancer.

How long will Onconova's conference presentation be archived?

Onconova's conference presentation will be archived for 90 days after it goes live.